CA2198316A1 - Treatment of septic shock with anti-tnf antibodies - Google Patents

Treatment of septic shock with anti-tnf antibodies

Info

Publication number
CA2198316A1
CA2198316A1 CA002198316A CA2198316A CA2198316A1 CA 2198316 A1 CA2198316 A1 CA 2198316A1 CA 002198316 A CA002198316 A CA 002198316A CA 2198316 A CA2198316 A CA 2198316A CA 2198316 A1 CA2198316 A1 CA 2198316A1
Authority
CA
Canada
Prior art keywords
shock
septic shock
tnf
mammal
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002198316A
Other languages
English (en)
French (fr)
Inventor
Gary Jesmok
Robert Gundel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of CA2198316A1 publication Critical patent/CA2198316A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA002198316A 1996-02-29 1997-02-24 Treatment of septic shock with anti-tnf antibodies Abandoned CA2198316A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60902296A 1996-02-29 1996-02-29
US08/609,022 1996-02-29

Publications (1)

Publication Number Publication Date
CA2198316A1 true CA2198316A1 (en) 1997-08-29

Family

ID=24439040

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002198316A Abandoned CA2198316A1 (en) 1996-02-29 1997-02-24 Treatment of septic shock with anti-tnf antibodies

Country Status (4)

Country Link
EP (1) EP0791360A3 (https=)
JP (1) JPH1025251A (https=)
AU (1) AU1487597A (https=)
CA (1) CA2198316A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10022113A1 (de) 2000-05-06 2001-11-15 Daimler Chrysler Ag Hybridantrieb für Kraftfahrzeuge
US20030161828A1 (en) * 2002-02-19 2003-08-28 Abbott Gmbh & Co. Kg Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure
DE60333228D1 (de) 2002-12-02 2010-08-12 Amgen Fremont Inc Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
WO2011158904A1 (ja) 2010-06-18 2011-12-22 株式会社林原生物化学研究所 アデノシンｎ１－オキシドを有効成分として含有する炎症性疾患治療剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8806339D0 (en) * 1988-03-17 1988-04-13 Hoffmann La Roche Monoclonal antibodies
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies

Also Published As

Publication number Publication date
EP0791360A2 (en) 1997-08-27
EP0791360A3 (en) 1997-09-24
AU1487597A (en) 1997-09-04
JPH1025251A (ja) 1998-01-27

Similar Documents

Publication Publication Date Title
Suffredini et al. Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration
CA2208673C (en) Composition for inhibiting intimal hyperplasia using pdgf antagonists and heparin
AU715338B2 (en) Methods for treatment of allergic asthma
Bahrami et al. Significance of TNF in hemorrhage-related hemodynamic alterations, organ injury, and mortality in rats
RU2477727C2 (ru) ПОЛИПЕПТИД, СЕЛЕКТИВНЫЙ ПО ОТНОШЕНИЮ К ИНТЕГРИНУ αvβ3, СПОСОБ ЕГО ПОЛУЧЕНИЯ, КОДИРУЮЩИЙ ЕГО ПОЛИНУКЛЕОТИД, КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ДАННЫЙ ПОЛИПЕПТИД, И СПОСОБ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ
CA1275951C (en) Lysing or blocking unwanted cells
US5336489A (en) Treatment of allograft rejection with IL-2 receptor-specific cytotoxins
US5620687A (en) Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors
MXPA98000760A (en) Methods for the treatment of asthma allergy
JPH04500068A (ja) 敗血症性ショックの治療および予防のための方法および組成物
JPH02234693A (ja) 炎症反応の調節方法
US20090087426A1 (en) Methods for Treatment of Allergic Asthma
Casas et al. Reconstituted high-density lipoprotein reduces LPS-stimulated TNFα
JP2002523379A (ja) 抗血栓薬およびヒト化抗フォンビルブランド因子モノクローナル抗体
Espat et al. PEG-BP-30 monotherapy attenuates the cytokine-mediated inflammatory cascade in baboon Escherichia coli septic shock
CA2198316A1 (en) Treatment of septic shock with anti-tnf antibodies
Ensinck et al. Endogenous somatostatin-28 modulates postprandial insulin secretion. Immunoneutralization studies in baboons.
US7537757B2 (en) Methods of facilitating vascular growth in cardiac muscle and methods for the production of recombinant EMAP II
JPS63263094A (ja) モノクローナル抗体
PL227130B1 (pl) Zastosowanie inhibitora IL -18 dowytwarzania leku
Skarlatos et al. Targeting of an anti-CR3 (CD11b/CD18) monoclonal antibody to spleen but not brain, in vivo in mice
OKANO et al. Effect of TCV-309, a novel platelet activating factor antagonist, on hemodynamics in dogs with endotoxin-induced shock
Carpenter Manipulation of T-Cell Populations to Abrogate Allograft Rejection
US20040191253A1 (en) Inhibition of intimal hyperplasia using antibodies to PDGF receptors
Kim et al. Kinetics of administered aggregated IgG in rats with passive Heymann's nephritis

Legal Events

Date Code Title Description
FZDE Dead